Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Over 400 variants in the cystic fibrosis (CF) transmembrane conductance regulator ( CFTR ) are CF-causing. CFTR modulators target variants to improve lung function, but marked variability in response exists and current therapies do not address all CF-causing variants highlighting unmet needs. Alternative epithelial ion channel/transporters such as SLC26A9 could compensate for CFTR dysfunction, providing therapeutic targets that may benefit all individuals with CF. We investigate the relationship between rs7512462, a marker of SLC26A9 activity, and lung function pre- and post-treatment with CFTR modulators in Canadian and US CF cohorts, in the general population, and in those with chronic obstructive pulmonary disease (COPD). Rs7512462 CC genotype is associated with greater lung function in CF individuals with minimal function variants (for which there are currently no approved therapies; p  = 0.008); and for gating ( p  = 0.033) and p.Phe508del/ p.Phe508del ( p  = 0.006) genotypes upon treatment with CFTR modulators. In parallel, human nasal epithelia with CC and p.Phe508del/p.Phe508del after Ussing chamber analysis of a combination of approved and experimental modulator treatments show greater CFTR function ( p  = 0.0022). Beyond CF, rs7512462 is associated with peak expiratory flow in a meta-analysis of the UK Biobank and Spirometa Consortium ( p  = 2.74 × 10 −44 ) and provides p  = 0.0891 in an analysis of COPD case-control status in the UK Biobank defined by spirometry. These findings support SLC26A9 as a therapeutic target to improve lung function for all people with CF and in individuals with other obstructive lung diseases.

[1]  L. Strug,et al.  A flexible summary statistics-based colocalization method with application to the mucin cystic fibrosis lung disease modifier locus , 2022, American journal of human genetics.

[2]  M. Amaral,et al.  Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9 , 2021, International journal of molecular sciences.

[3]  M. Myerburg,et al.  Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia (HBE). , 2021, American journal of physiology. Lung cellular and molecular physiology.

[4]  L. Strug,et al.  A flexible summary-based colocalization method with application to the mucin Cystic Fibrosis lung disease modifier locus , 2021, bioRxiv.

[5]  Jamie L. Marshall,et al.  Single-nucleus cross-tissue molecular reference maps to decipher disease gene function , 2021, bioRxiv.

[6]  G. Cutting,et al.  SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  J. Rommens,et al.  Cystic fibrosis–related diabetes onset can be predicted using biomarkers measured at birth , 2021, Genetics in Medicine.

[8]  I. Sermet-Gaudelus,et al.  Modulators of CFTR. Updates on clinical development and future directions. , 2021, European journal of medicinal chemistry.

[9]  J. Clancy,et al.  Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial , 2021, Annals of the American Thoracic Society.

[10]  J. Rommens,et al.  LocusFocus: Web-based colocalization for the annotation and functional follow-up of GWAS , 2020, PLoS Comput. Biol..

[11]  J. Clancy,et al.  Clinical Effectiveness of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients Homozygous for F508del-CFTR. , 2020, Annals of the American Thoracic Society.

[12]  C. Bear,et al.  A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations , 2020, European Respiratory Journal.

[13]  S. Larsson,et al.  Alcohol Consumption and Cardiovascular Disease , 2020, Circulation. Genomic and precision medicine.

[14]  L. Goff,et al.  Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. , 2019, The Journal of clinical investigation.

[15]  R. Irizarry.  ggplot2 , 2019, Introduction to Data Science.

[16]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[17]  Matthew R. Robinson,et al.  Accurate, scalable and integrative haplotype estimation , 2019, Nature Communications.

[18]  Yukiko Sato,et al.  The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del–CFTR , 2019, The Journal of Biological Chemistry.

[19]  J. Rommens,et al.  Genetic modifiers of cystic fibrosis-related diabetes have extensive overlap with type 2 diabetes and related traits. , 2019, The Journal of clinical endocrinology and metabolism.

[20]  Christopher D. Brown,et al.  The GTEx Consortium atlas of genetic regulatory effects across human tissues , 2019, Science.

[21]  Irving L. Weissman,et al.  A molecular cell atlas of the human lung from single cell RNA sequencing , 2019, Nature.

[22]  O. Andreassen,et al.  A global overview of pleiotropy and genetic architecture in complex traits , 2019, Nature Genetics.

[23]  Marta Sawicka,et al.  Cryo-EM structures and functional characterization of murine Slc26a9 reveal mechanism of uncoupled chloride transport , 2019, eLife.

[24]  M. Amaral,et al.  Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[25]  Susan Redline,et al.  Operating Characteristics of the Rank-Based Inverse Normal Transformation for Quantitative Trait Analysis in Genome-Wide Association Studies , 2019, bioRxiv.

[26]  J. Rommens,et al.  Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci , 2019, PLoS genetics.

[27]  S. Stanojevic,et al.  The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[28]  Lisa J. Strug,et al.  VikNGS: a C++ variant integration kit for next generation sequencing association analysis , 2018, bioRxiv.

[29]  Masa Umicevic Mirkov,et al.  A global overview of pleiotropy and genetic architecture in complex traits , 2018, bioRxiv.

[30]  Benjamin B. Sun,et al.  New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. , 2018, Nature Genetics.

[31]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[32]  A. Balázs,et al.  Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis , 2018, Front. Pharmacol..

[33]  L. Strug,et al.  Recent advances in developing therapeutics for cystic fibrosis. , 2018, Human molecular genetics.

[34]  P. Böelle,et al.  SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis , 2018, Front. Pharmacol..

[35]  Gavin Band,et al.  BGEN: a binary file format for imputed genotype and haplotype data , 2018, bioRxiv.

[36]  S. Scherer,et al.  Improving imputation in disease-relevant regions: lessons from cystic fibrosis , 2018, npj Genomic Medicine.

[37]  M. Corey,et al.  Reference percentiles of FEV1 for the Canadian cystic fibrosis population: comparisons across time and countries , 2018, Thorax.

[38]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[39]  T. Hwang,et al.  Ion channels as targets to treat cystic fibrosis lung disease. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[40]  K. Giuliano,et al.  Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors , 2017, SLAS discovery : advancing life sciences R & D.

[41]  D. Madden,et al.  The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9. , 2017, American journal of physiology. Lung cellular and molecular physiology.

[42]  Gad Abraham,et al.  FlashPCA2: principal component analysis of biobank-scale genotype datasets , 2016, bioRxiv.

[43]  J. Rommens,et al.  Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics , 2016, Human molecular genetics.

[44]  M. Mall.  Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. , 2016, Annals of the American Thoracic Society.

[45]  J. Füllekrug,et al.  Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[46]  Hugo M. Botelho,et al.  Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides , 2016, Human mutation.

[47]  M. Brodlie,et al.  Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets , 2015, Thorax.

[48]  J. Rommens,et al.  Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis , 2015, Nature Communications.

[49]  M. Mall,et al.  Targeting ion channels in cystic fibrosis. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[50]  Emmanouil T. Dermitzakis,et al.  Fast and efficient QTL mapper for thousands of molecular phenotypes , 2015, bioRxiv.

[51]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[52]  Melissa R. Miller,et al.  Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. , 2015, The Journal of pediatrics.

[53]  Timothy A Thornton,et al.  Robust Inference of Population Structure for Ancestry Prediction and Correction of Stratification in the Presence of Relatedness , 2015, Genetic epidemiology.

[54]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[55]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[56]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[57]  J. Walters,et al.  Diagnosis and early detection of COPD using spirometry. , 2014, Journal of thoracic disease.

[58]  U. Seidler,et al.  Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3- transport and reduces survival in CFTR-deficient mice , 2014, Pflügers Archiv - European Journal of Physiology.

[59]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[60]  Melissa R. Miller,et al.  Evidence for a Causal Relationship Between Early Exocrine Pancreatic Disease and Cystic Fibrosis–Related Diabetes: A Mendelian Randomization Study , 2014, Diabetes.

[61]  H. Fischer.  The G551D CFTR chloride channel spurs the development of personalized medicine , 2014, The Journal of physiology.

[62]  J. Clancy,et al.  Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. , 2013, American journal of respiratory and critical care medicine.

[63]  J. Rommens,et al.  Genetic Modifiers of Cystic Fibrosis–Related Diabetes , 2013, Diabetes.

[64]  George P Patrinos,et al.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.

[65]  A. Gaggar,et al.  Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. , 2013, Chest.

[66]  M. Dransfield,et al.  A Pharmacologic Approach to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Smoking Related Lung Disease , 2012, PloS one.

[67]  F. van Goor,et al.  Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[68]  Michael R Knowles,et al.  Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis , 2012, Nature Genetics.

[69]  R. Durbin,et al.  Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses , 2012, Nature Protocols.

[70]  J. Riordan,et al.  Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[72]  M. Corey,et al.  A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies , 2011, Pediatric pulmonology.

[73]  P. Robinson,et al.  Whole-exome sequencing for finding de novo mutations in sporadic mental retardation , 2010, Genome Biology.

[74]  Josyf Mychaleckyj,et al.  Robust relationship inference in genome-wide association studies , 2010, Bioinform..

[75]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[76]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[77]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[78]  J. Pilewski,et al.  SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia , 2009, The Journal of general physiology.

[79]  Kenneth S. Yew,et al.  Diagnosis of chronic obstructive pulmonary disease. , 2008, American family physician.

[80]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[81]  D. Reich,et al.  Population Structure and Eigenanalysis , 2006, PLoS genetics.

[82]  J. Zieleński,et al.  Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. , 2006, American journal of respiratory and critical care medicine.

[83]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[84]  A. Gionis.  Data Analysis , 1996, Data Sci. J..

[85]  D. Bedwell,et al.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations , 1996, Nature Medicine.

[86]  E. Steyerberg,et al.  Focus on : Contemporary Methods in Biostatistics ( I ) Regression Modeling Strategies , 2017 .

[87]  J. Elborn,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[88]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[89]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[90]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .